SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
SELLAS Life Sciences Group, Inc. (SLS)
Last sellas life sciences group, inc. earnings: 11/14 04:41 pm
Check Earnings Report
US:NYSE Investor Relations:
sellaslifesciences.com/investors/overview/default.aspx
Company Research
Source: GlobeNewswire
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung Cancers and Acute Myeloid Leukemia - - First Clinical Data Expected in First Quarter of 2020 - NEW YORK, July 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced the dosing of the first patient in its Phase 1/2 open-label study of GPS in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with selected WT1-positive advanced cancers, including both solid tumors and hematologic malignances. “This is an important milestone as this study allows us to potentially enhance our safety and activity profile of GPS in combination with anti-PD-1 therapies, pa
Show less
Read more
Impact Snapshot
Event Time:
SLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLS alerts
High impacting SELLAS Life Sciences Group, Inc. news events
Weekly update
A roundup of the hottest topics
SLS
News
- SELLAS Life Sciences GAAP EPS of -$0.10 beats by $0.03 [Seeking Alpha]Seeking Alpha
- SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024GlobeNewswire
- SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia [Yahoo! Finance]Yahoo! Finance
- SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid LeukemiaGlobeNewswire
SLS
Sec Filings
- 11/13/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 11/8/24 - Form SC
- SLS's page on the SEC website